Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 504

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 504
---
 the other hand
     
    10-K
     
    001-14895
     
    10.66
     
    3/1/22

     10.57†
     
    Letter Agreement, dated November 18, 2022, between Sarepta Therapeutics, Inc. and Douglas S. Ingram
     
    10-K
     
    001-14895
     
    10.72
     
    2/28/23

     10.58
     
    Sarepta Therapeutics Inc.'s Policy for Recoupment of Incentive Compensation
     
    10-K
     
    001-14895
     
    10.77
     
    2/28/24

     10.59^
     
    Amended and Restated Lead DMD ProductManufacturing and Supply Agreement betweenCatalent Maryland, Inc. and Sarepta Therapeutics Three, LLC
     
    10-Q
     
    001-14895
     
    10.1
     
    8/2/23

     10.60^
     
    Exclusive License Agreement between the Research Institute at Nationwide Children's Hospital and Sarepta Therapeutics, Inc., dated October 8, 2018
     
    10-Q
     
    001-14895
     
    10.2
     
    8/2/23

     10.61^
     
    First Amendment to the Amended and Restated Lead DMD Product Manufacturing & Supply Agreement between Catalent Maryland, Inc. and Sarepta Therapeutics Three, LLC
     
    10-Q
     
    001-14895
     
    10.5
     
    8/2/23

     10.62
     
    Amendment No. 2 to the Sarepta Therapeutics, Inc. Amended and Restated 2013 Employee Stock Purchase Plan
     
    8-K
     
    001-14895
     
    10.2
     
    6/9/23

     10.63
     
    Amendment No. 3 to the Sarepta Therapeutics, Inc.2018 Equity Incentive Plan
     
    8-K